Oxybutynin/pilocarpine

Drug Profile

Oxybutynin/pilocarpine

Alternative Names: pilocarpine/oxybutynin; THVD-101a; THVD-102

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator TheraVida
  • Class Alkaloids; Carbocyclic acids; Furans; Imidazoles; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperhidrosis; Overactive bladder

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Aug 2015 Phase-II clinical trials in Hyperhidrosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top